Ravuconazole

From Self-sufficiency
Jump to: navigation, search
Ravuconazole
File:Ravuconazole.svg
Systematic (IUPAC) name
4-[2-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
Identifiers
CAS Number 182760-06-1
ATC code none
PubChem CID 467825
Chemical data
Formula C22H17F2N5OS
Molar mass 437.465086 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Ravuconazole (BMS-207147 and ER-30346) is a potent triazole antifungal, being developed by Bristol-Myers Squibb, that is currently in phase I/II clinical trials. [1]. The drug has a shown to have a similar spectrum of activity to voriconazle, with an increased half-life.[2] However, ravuconazole has limited activity against species of fusarium, scedosporium and zygomycetes.[3][4]

  1. National Cancer Institute. Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Feb 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00064311?term=ravuconazole&spons_ex=Y&rank=1 NLM Identifier: NCT00064311.
  2. Pasqualotto AC, Denning DW. Ravuconazole. The Aspergillus Website. http://www.aspergillus.org.uk. Date accessed: 2010 Feb 18.
  3. Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs. 2010 Feb;11(2):165-74.
  4. Pfaller MA, Messer SA, Hollis RJ, Jones RN, et al. Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi. Antimicrob Agents Chemother. 2002 April; 46(4): 1032–1037. doi: 10.1128/AAC.46.4.1032-1037.2002.